Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes

被引:15
作者
Berer, A
Jäger, E
Sagaster, V
Streubel, B
Wimazal, F
Sperr, WR
Welterman, A
Schwarzinger, I
Frommlet, F
Haas, OA
Valent, P
Lechner, K
Geissler, K
Öhler, L
机构
[1] Univ Vienna, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Pathol, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria
[4] Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria
[5] St Anna Childrens Hosp, CCRI, A-1090 Vienna, Austria
关键词
myelodysplastic syndromes; circulating myeloid progenitor cells; survival; AML transformation; risk factor;
D O I
10.1007/s00277-003-0619-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The growth characteristics and the prognostic value of cytokine-stimulated myeloid colony formation from peripheral blood mononuclear cells (PBMC) of patients with myelodysplastic syndromes (MDS) are largely unknown. In this study we have determined the number of myeloid colony-forming units (mCFUs) in semisolid medium from 112 MDS patients and correlated them with French-American-British (FAB) type, the international prognostic scoring system (IPSS), karyotype, peripheral blood (PB) and bone marrow (BM) blast cells, cytopenias, lactate dehydrogenase (LDH), and survival data. Concerning the FAB classification, lower median mCFUs were found in patients with refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) compared to refractory anemia with excess of blast cells (RAEB) and refractory anemia with excess of blasts cells in transformation (RAEB-T). In vitro growth in MDS clearly correlated with the cytogenetic risk groups defined by the IPSS (30.5/10(5) PBMCs with favorable karyotypes, 191 in the intermediate prognostic group, 677 with unfavorable cytogenetics, p = 0.015 favorable vs unfavorable). BM blast cells > 5% (60.5 vs 255 colonies, p = 0.032) as well as LDH levels above the normal limit (64.5 vs 425 colonies, p = 0.045) were also associated with higher colony formation. Patients were stratified according to the number of circulating mCFUs into a low growth, intermediate growth and high growth group. Median survival was 343 days in the high growth, 1119 days in the low growth, and 2341 days in the intermediate growth group (p = 0.0002). Multivariate analyses revealed colony growth (p = 0.0056), PB blast cells (p = 0.0069), cytogenetic risk group (p = 0.024), and platelet count (p = 0.018) to predict survival in our patients. After inclusion of the IPSS risk categories, mCFU levels remained a highly predictive parameter for survival (p = 0.0056) and acute myeloblastic leukemia (AML) transformation (p = 0.0003).
引用
收藏
页码:271 / 277
页数:7
相关论文
共 24 条
[1]  
AUL C, 1992, LEUKEMIA, V6, P52
[2]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[3]  
CARBONELL F, 1985, BLOOD, V66, P463
[4]   Fluorescence in situ hybridization on methylcellulose cultured hematopoietic stem cells from myelodysplastic syndromes [J].
Dupont, JM ;
Fontenay-Roupie, M ;
Dupuy, O ;
Lebarr, A ;
Le Tessier, D ;
Auvinet, P ;
Rabineau, D ;
Fichelson, S .
CANCER GENETICS AND CYTOGENETICS, 1998, 101 (01) :12-15
[5]  
EMERSON SG, 1989, BLOOD, V74, P49
[6]  
FONATSCH C, 1998, NEW DIAGNOSTIC METHO, P113
[7]  
FRANCIS GE, 1983, LANCET, V1, P1409
[8]   Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t;: novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry [J].
Fuchigami, K ;
Mori, H ;
Matsuo, T ;
Iwanaga, M ;
Nagai, K ;
Kuriyama, K ;
Tomonaga, M .
LEUKEMIA RESEARCH, 2000, 24 (02) :163-174
[9]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[10]  
Mitelman F, 1995, ISCN INT SYSTEM HUMA